RGEN
Repligen Corporation158.09
-2.49-1.55%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Key Stats
Market Cap
8.90BP/E (TTM)
7904.50Basic EPS (TTM)
0.02Dividend Yield
0%Recent Filings
10-K
8-K
8-K
10-Q
Q3 FY2025 results
Repligen surged to $188.8M revenue in Q3 ended September 30, 2025, up 21.9% y/y from $154.9M while gross margin expanded to 53.2% from 50.0% on lower excess inventory costs and sales leverage. Operating income flipped to $16.8M profit from $7.8M loss, diluted EPS hit $0.26 versus $(0.01), reconciling cleanly to 56.5M shares. YTD revenue climbed 15.7% to $540.3M, operating income $37.3M, EPS $0.63, fueled by proteins, chromatography, and analytics franchises plus $6.9M from March 2025's $69.9M 908 Devices PAT Portfolio acquisition (provisional $50.1M goodwill, $13.6M finite-lived intangibles over 8-14 years). Cash sits at $748.7M after $91.7M operating cash flow, offset by acquisition spend; $538M Convertible Notes due 2028 carry on. Acquisitions build new modality firepower. Yet supply chain disruptions linger as a key risk.
8-K
Q3 revenue beats, guidance up
Repligen Corporation reported third-quarter 2025 revenue of $189 million, up 22% reported and 18% organic from $155 million a year earlier, with double-digit growth across all franchises and geographies. Orders surged over 20% year-over-year, fueling broad momentum in consumables and capital equipment. The company raised full-year revenue guidance to $729-$737 million, signaling 14%-15.5% non-COVID organic growth. Strong execution persists, yet integration costs linger.
IPO
Website
Employees
Sector
Industry
AVTR
Avantor, Inc.
11.20-0.08
CLGN
CollPlant Biotechnologies Ltd.
1.53-0.14
DHR
Danaher Corporation
224.70-3.83
ORGO
Organogenesis Holdings Inc.
5.17+0.34
QGEN
Qiagen N.V.
45.01-0.43
RGNT
Regentis Biomaterials Ltd.
6.05-0.84
RSCF
Reflect Scientific, Inc.
0.05+0.00
RVTY
Revvity, Inc.
96.27-2.81
SOAGY
Sartorius AG
56.43-0.16
TECH
Bio-Techne Corp
57.44-1.25